Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RA190 inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor RPN13.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 52.00 | |
5 mg | In stock | $ 117.00 | |
10 mg | In stock | $ 171.00 | |
25 mg | In stock | $ 258.00 | |
50 mg | In stock | $ 460.00 | |
100 mg | In stock | $ 676.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 153.00 |
Description | RA190 inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor RPN13. |
Targets&IC50 | HeLa cells:0.15 μM |
In vitro | Multiple myeloma (MM) lines, even those resistant to bortezomib, are sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. RA190 stabilizes targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially kills HPV-transformed cells. |
In vivo | RA190 administration profoundly reduces growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retards HPV16+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses. |
Molecular Weight | 596.76 |
Formula | C28H23Cl5N2O2 |
CAS No. | 1617495-03-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95mg/ml (159.19 Mm)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RA190 1617495-03-0 Proteases/Proteasome Ubiquitination Proteasome RA 190 inhibit RA-190 Inhibitor inhibitor